Opens in a new tab

Corporate Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates (ADCs). Our pipeline includes varegacestat, an investigational, oral, once-daily gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radiotherapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Latest News

November 9, 2026 
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update

READ MORE

November 6, 2026 
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

November 4, 2026 
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

READ MORE

November 2, 2026 
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

READ MORE

October 30, 2026 
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

READ MORE

October 26, 2026 
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

READ MORE

October 6, 2026 
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

September 30, 2026 
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

READ MORE

September 8, 2026 
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

September 2, 2026 
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

READ MORE

VIEW ALL NEWS →

Latest Presentation

December 2025

Immunome Topline Call Presentation
Download PDF

October 2026

Immunome Corporate Presentation
Download PDF

Latest Event

12/01/2026

9th Annual Evercore Healthcare Conference at 9:10a.m. EST

Webcast
View All Events